ストックスクリーナーアプリを入手
255.77
0.05%
0.13
前日終値:
$255.64
開ける：
$262.54
24時間の取引高:
180.35K
Relative Volume:
0.37
時価総額：
$26.40B
収益：
$3.81B
当期純損益:
$-644.79M
株価収益率:
-40.99
EPS:
-6.24
ネットキャッシュフロー:
$-669.77M
1週間 パフォーマンス:
+4.44%
1か月 パフォーマンス:
-6.92%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$254.37
$262.76
1週間の範囲:
$246.04
$267.00
52週間の値動き範囲:
$172.67
$287.88
Beigene Ltd Adr Stock (ONC) Company Profile
名前
Beigene Ltd Adr
セクター
電話
13459494123
住所
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
ONC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
Beigene Ltd Adr Stock (ONC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-03-03 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-12-03 | 再開されました | Morgan Stanley | Overweight |
| 2024-09-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-02-06 | 再開されました | JP Morgan | Overweight |
| 2023-09-12 | 開始されました | Macquarie | Outperform |
| 2023-08-17 | 開始されました | Jefferies | Buy |
| 2023-07-17 | 開始されました | Citigroup | Buy |
| 2023-06-30 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2023-01-12 | 開始されました | Daiwa Securities | Buy |
| 2022-10-13 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-10-13 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-09 | 再開されました | JP Morgan | Overweight |
| 2022-03-17 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-02-07 | 開始されました | Deutsche Bank | Buy |
| 2021-10-12 | 開始されました | Bernstein | Outperform |
| 2021-10-06 | アップグレード | CLSA | Underperform → Buy |
| 2021-03-08 | 開始されました | China Renaissance | Buy |
| 2021-03-01 | ダウングレード | CLSA | Outperform → Underperform |
| 2020-11-09 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-06 | ダウングレード | Maxim Group | Buy → Hold |
| 2020-11-06 | ダウングレード | Piper Sandler | Neutral → Underweight |
すべてを表示
Beigene Ltd Adr (ONC) 最新ニュース
BeiGene wins patent challenge against Pharmacyclics By Investing.com - Investing.com India
BeiGene wins US patent dispute over cancer drug - Investing.com
BeiGene reports financial results under PRC GAAP By Investing.com - Investing.com South Africa
BeiGene reports financial results under PRC GAAP - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? - Yahoo Finance
Why Summit Therapeutics Rocketed Double-Digits Today - The Motley Fool
BigBear.ai Holdings Inc (BBAI) gets rating Downgrade from Northland Capital - knoxdaily.com
Morgan Stanley analysts upgrades an Equal-weight rating for Urban Edge Properties (UE) - knoxdaily.com
RBC Capital Mkts initates BeiGene Ltd. ADR (ONC) rating to an Outperform - knoxdaily.com
BGNE Page Not Found - Benzinga
Beigene’s Wang Xiaodong sells $10.1m in stock By Investing.com - Investing.com India
Beigene’s Wang Xiaodong sells $10.1m in stock - Investing.com
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? - Yahoo Finance
Permian Resources Corp [PR] Director makes an insider purchase of 250,000 shares worth 3.02 million. - knoxdaily.com
RBC Capital sets BeiGene stock Outperform with $312 target By Investing.com - Investing.com South Africa
RBC Capital sets BeiGene stock Outperform with $312 target - Investing.com
JMP reiterates BeiGene stock with $348 target despite trial halt - Investing.com India
Beigene’s president Wu Xiaobin sells $14.6 million in shares - Investing.com
Beigene’s president Wu Xiaobin sells $14.6 million in shares By Investing.com - Investing.com India
Macquarie Prefers Biotechs Over CDMOs; Top Picks BEIGENE/ AKESO - AASTOCKS.com
Beigene director Wang Xiaodong sells $10.9 million in shares By Investing.com - Investing.com South Africa
Beigene director Wang Xiaodong sells $10.9 million in shares - Investing.com India
Beigene’s Wu Xiaobin anticipates $1.06 million from RMB shares sale - Investing.com
Bernstein raises BeiGene stock price target to $259 - Investing.com
BeiGene CEO John Oyler sells $10 million in shares - Investing.com India
Beigene CEO John Oyler sells $10.39 million in shares By Investing.com - Investing.com South Africa
Beigene CEO John Oyler sells shares worth $14.6 million - Investing.com India
BeiGene Stock: Top Executives Sell Shares Near Record High - Sharewise
Beigene CEO John Oyler sells shares worth $14.6 million By Investing.com - Investing.com South Africa
Beigene CEO John Oyler sells $10.39 million in shares - Investing.com
BeiGene Ltd. Sponsored ADR to Host Earnings Call - ACCESS Newswire
Beigene chair Wang Xiaodong sells shares worth over $2 million - Investing.com India
Beigene president sells economic interest in RMB shares for $1.16 million - Investing.com India
BOCOMI: BEIGENE (06160.HK) Guides to Positive 2025 Operating Profit; Rating Kept at Buy - AASTOCKS.com
JPMorgan maintains BeiGene stock Overweight rating, $311 target - Investing.com India
Beigene SVP sells $331,375 in American depositary shares By Investing.com - Investing.com South Africa
Beigene SVP sells $331,375 in American depositary shares - Investing.com India
JPMorgan maintains BeiGene stock Overweight rating, $311 target By Investing.com - Investing.com South Africa
BofA lifts BeiGene stock rating, raises target to $320 - Investing.com India
BofA lifts BeiGene stock rating, raises target to $320 By Investing.com - Investing.com South Africa
Beigene directors Julian and Felix Baker sell $190m in shares - Investing.com India
BeiGene gets FDA Orphan Drug Designation for sonrotocla - Investing.com
Guggenheim lifts BeiGene stock target to $348, maintains Buy rating - Investing.com India
Citizens JMP lifts BeiGene stock target to $348 on strong sales By Investing.com - Investing.com South Africa
Citizens JMP lifts BeiGene stock target to $348 on strong sales - Investing.com India
AASTOCKS Financial NewsBeiGene, Ltd. (ONC) - AASTOCKS.com
Beigene Ltd Adr (ONC) 財務データ
収益
当期純利益
現金流量
EPS
2.45%
大文字化:
|
ボリューム (24 時間):